{"id":"methotrexate-hydrocortisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Immunosuppression/Infection"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL2106309","moleculeType":"Small molecule","molecularWeight":"460.57"},"_fixedAt":"2026-03-30T17:34:31.819519","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is an antimetabolite that blocks folate metabolism, reducing DNA synthesis and cell division in rapidly proliferating cells. Hydrocortisone is a corticosteroid that suppresses immune responses and inflammation. Together, this combination targets both malignant cell growth and inflammatory/immune-mediated complications, commonly used in hematologic malignancies and graft-versus-host disease (GVHD) prophylaxis.","oneSentence":"Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation, while hydrocortisone provides anti-inflammatory and immunosuppressive effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:57.843Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT06177067","phase":"PHASE1","title":"Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-04-19","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":24},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":850},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":100},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT06247787","phase":"PHASE1","title":"A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-02-04","conditions":"Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia","enrollment":36},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT00400946","phase":"PHASE3","title":"05-001: Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-04","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":800},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":128},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT07387926","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-26","conditions":"Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT05656248","phase":"PHASE2","title":"Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-01-17","conditions":"Myeloid Neoplasm","enrollment":25},{"nctId":"NCT06895473","phase":"PHASE2","title":"Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-04","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":26},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT04898894","phase":"PHASE1","title":"Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-11-15","conditions":"Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage","enrollment":37},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT00136435","phase":"PHASE2","title":"A Study in Adults With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2002-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT04501614","phase":"PHASE1, PHASE2","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-02-24","conditions":"Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)","enrollment":11},{"nctId":"NCT05192889","phase":"PHASE1, PHASE2","title":"Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-08-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT05745714","phase":"PHASE1, PHASE2","title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT07175415","phase":"PHASE1, PHASE2","title":"HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2026-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory","enrollment":42},{"nctId":"NCT05658640","phase":"PHASE1, PHASE2","title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-11-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT05751044","phase":"PHASE1, PHASE2","title":"HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia","enrollment":461},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT03817320","phase":"PHASE1, PHASE2","title":"PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2019-02-12","conditions":"ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood","enrollment":24},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT03813147","phase":"PHASE1","title":"Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-17","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":12},{"nctId":"NCT03792256","phase":"PHASE1","title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2019-04-11","conditions":"Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma","enrollment":12},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":78},{"nctId":"NCT04029688","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-01-27","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma","enrollment":38},{"nctId":"NCT05476770","phase":"PHASE1","title":"Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","status":"RECRUITING","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2022-11-11","conditions":"Hematologic Malignancy, AML, ALL","enrollment":54},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT03635957","phase":"PHASE4","title":"Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-09-26","conditions":"Gout","enrollment":14},{"nctId":"NCT05740449","phase":"PHASE1, PHASE2","title":"HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"WITHDRAWN","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":""},{"nctId":"NCT06269536","phase":"NA","title":"Stress-reducing Intervention in Urothelial Carcinoma","status":"RECRUITING","sponsor":"Comenius University","startDate":"2024-02-15","conditions":"Bladder Cancer","enrollment":50},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT05320380","phase":"PHASE1, PHASE2","title":"A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2023-08-01","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia","enrollment":""},{"nctId":"NCT01614197","phase":"PHASE1","title":"A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2015-07-03","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma","enrollment":16},{"nctId":"NCT03194932","phase":"PHASE1","title":"Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-07-11","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT03349281","phase":"PHASE1","title":"Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL","status":"COMPLETED","sponsor":"Julio Barredo, MD","startDate":"2019-03-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":6},{"nctId":"NCT03286634","phase":"PHASE2","title":"ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016","status":"RECRUITING","sponsor":"National Hospital Organization Nagoya Medical Center","startDate":"2017-04-18","conditions":"Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer","enrollment":60},{"nctId":"NCT01700946","phase":"PHASE2","title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-04-15","conditions":"Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":"Lymphoblastic Lymphoma","enrollment":23},{"nctId":"NCT00006455","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"1999-11-26","conditions":"Lymphoma","enrollment":885},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":"Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma","enrollment":31},{"nctId":"NCT01187810","phase":"PHASE1","title":"Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL","status":"TERMINATED","sponsor":"South Plains Oncology Consortium","startDate":"2010-08","conditions":"Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma","enrollment":3},{"nctId":"NCT02481310","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2015-10-28","conditions":"Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":38},{"nctId":"NCT02776605","phase":"PHASE2","title":"Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2016-06","conditions":"ALL","enrollment":30},{"nctId":"NCT05049473","phase":"PHASE2","title":"Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2014-01","conditions":"Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL","enrollment":100},{"nctId":"NCT01861002","phase":"PHASE1","title":"A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2013-05-22","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood","enrollment":15},{"nctId":"NCT01104025","phase":"PHASE2","title":"Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-04","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":31},{"nctId":"NCT03515200","phase":"PHASE1","title":"Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-04-20","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission","enrollment":12},{"nctId":"NCT04486027","phase":"","title":"Can Cytokines be Used as an Activation Marker","status":"COMPLETED","sponsor":"Maltepe University","startDate":"2017-04-05","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT03071276","phase":"PHASE2","title":"Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-14","conditions":"Acute Myeloid Leukemia (AML)","enrollment":37},{"nctId":"NCT00720109","phase":"PHASE2, PHASE3","title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":63},{"nctId":"NCT00853008","phase":"PHASE4","title":"Treatment of High Risk Adult Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2003-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT02212561","phase":"PHASE1","title":"Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-08","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)","enrollment":19},{"nctId":"NCT01540812","phase":"","title":"Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2012-02","conditions":"Acute Lymphoblastic Leukemia","enrollment":418},{"nctId":"NCT00440726","phase":"PHASE1, PHASE2","title":"Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2006-08-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":31},{"nctId":"NCT01887587","phase":"PHASE1","title":"Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia","status":"TERMINATED","sponsor":"Ehab L Atallah","startDate":"2013-06","conditions":"Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":5},{"nctId":"NCT02535806","phase":"PHASE2","title":"Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults","status":"TERMINATED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2015-07","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":2},{"nctId":"NCT00550992","phase":"NA","title":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","status":"UNKNOWN","sponsor":"Dutch Childhood Oncology Group","startDate":"2006-01","conditions":"Leukemia","enrollment":445},{"nctId":"NCT02518750","phase":"PHASE2","title":"Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-11-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell","enrollment":3},{"nctId":"NCT00928200","phase":"PHASE1","title":"Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2009-04-13","conditions":"Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase","enrollment":1},{"nctId":"NCT02676323","phase":"PHASE1","title":"Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-05-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":19},{"nctId":"NCT00133991","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-07","conditions":"Leukemia, Lymphoma","enrollment":23},{"nctId":"NCT00002865","phase":"PHASE2","title":"High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"1995-04","conditions":"Leukemia","enrollment":25},{"nctId":"NCT00392834","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2006-09","conditions":"Lymphoma","enrollment":34},{"nctId":"NCT02451774","phase":"PHASE2, PHASE3","title":"Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction","status":"UNKNOWN","sponsor":"Ramón Óscar González-Ramella, Ph.D","startDate":"2015-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":44},{"nctId":"NCT00354107","phase":"PHASE1, PHASE2","title":"Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01","conditions":"Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma","enrollment":5},{"nctId":"NCT02419755","phase":"PHASE2","title":"Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-04-14","conditions":"Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia","enrollment":12},{"nctId":"NCT00098839","phase":"PHASE1, PHASE2","title":"Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-02","conditions":"Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":134},{"nctId":"NCT02433483","phase":"PHASE2","title":"Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-05-22","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":4},{"nctId":"NCT02270788","phase":"PHASE1","title":"Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-04-02","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT03123718","phase":"PHASE3","title":"High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL","status":"UNKNOWN","sponsor":"Chonnam National University Hospital","startDate":"2017-07-01","conditions":"DLBCL","enrollment":205},{"nctId":"NCT00096135","phase":"NA","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-11","conditions":"Leukemia","enrollment":168},{"nctId":"NCT00002744","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-05","conditions":"Leukemia","enrollment":1970},{"nctId":"NCT00873093","phase":"PHASE2","title":"Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03","conditions":"B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia","enrollment":148},{"nctId":"NCT00002494","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1992-05","conditions":"Leukemia, Lymphoma","enrollment":134},{"nctId":"NCT00084838","phase":"PHASE2","title":"Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2003-02","conditions":"Central Nervous System Tumor, Pediatric","enrollment":25},{"nctId":"NCT00057811","phase":"PHASE2","title":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-06","conditions":"Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma","enrollment":97},{"nctId":"NCT00002785","phase":"PHASE2","title":"Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-07","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00002757","phase":"PHASE3","title":"TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2001-06","conditions":"Leukemia, Lymphoma","enrollment":1148},{"nctId":"NCT00002805","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1997-08","conditions":"Leukemia","enrollment":115},{"nctId":"NCT00176462","phase":"PHASE2","title":"CINJALL: Treatment for Children With Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2001-02","conditions":"Acute Lymphocytic Leukemia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"HYPERTENSION"},{"count":1,"reaction":"ABDOMINAL COMPARTMENT SYNDROME"},{"count":1,"reaction":"DRUG TOLERANCE DECREASED"},{"count":1,"reaction":"FEBRILE NEUTROPENIA"},{"count":1,"reaction":"FUNGAL INFECTION"},{"count":1,"reaction":"HEPATIC FAILURE"},{"count":1,"reaction":"MENTAL STATUS CHANGES"},{"count":1,"reaction":"PANCYTOPENIA"},{"count":1,"reaction":"RENAL FAILURE"},{"count":1,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2014 Aug","pmid":"24977988","title":"Diffuse anterior scleritis and secondary glaucoma as a manifestation of adult T-cell prolymphocytic leukemia.","journal":"Cornea"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Methotrexate/Hydrocortisone","genericName":"Methotrexate/Hydrocortisone","companyName":"Dana-Farber Cancer Institute","companyId":"dana-farber-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation, while hydrocortisone provides anti-inflammatory and immunosuppressive effects. Used for Acute lymphoblastic leukemia (ALL), Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}